GU Oncology Now

? In our new star-studded roundtable, moderator Katy Beckermann and guests Sumanta Pal, MD, FASCO, Toni Choueiri, Hans Hammers, and Pedro C Barata, MD MSc FACP, discuss ICIs and TKIs in #RCC and the impact of these strategies on treatment. ?? Watch the first part now, which focuses on the differences between the TiNivo-2 and CONTACT-3 trials: https://buff.ly/3Zkg6bF

?? While VEGF TKIs are a common therapy for the treatment of metastatic #ccRCC, VEGF upregulation can occur as a resistance measure against the treatment. ?? In a study presented at #IKCS by Dr. Saby George of Roswell Park Comprehensive Cancer Center, researchers hypothesized that utilizing #bevacizumab during breaks in #pazopanib treatment can result in less toxicity while binding and neutralizing VEGF:

?? Clarity Pharmaceuticals has begun their trial comparing the diagnostic efficacy of 64Cu-SAR-bisPSMA, against the current standard-of-care, 68Ga-PSMA-11, in detecting #prostatecancer recurrence. ?? Learn more about the trial's goals and the advantages of 64Cu-SAR-bisPSMA:

?? In the second part of our interview with Drs. Michael Whalen and Vincent Xu of The George Washington University Cancer Center, Dr. Xu discusses the next steps for their study on NAC for UTUC, along with potential alternative treatments for patients who are ineligible for chemotherapy. ?? Watch the full video here: https://buff.ly/4hUtxrc

?? While the PIVOT-02 trial found that #BEMPEG plus #nivolumab displayed benefits over ICI monotherapy for patients with advanced urothelial carcinoma, PIVOT-10 showed that the combination did not meet the efficacy threshold for ORR in the study’s patient population. Learn more:

?? A recent study led by Justin Refugia of Wake Forest University School of Medicine sought to determine if sequential intravesical chemotherapy with #gemcitabine and #docetaxel provides similar oncologic outcomes to BCG in patients with treatment-na?ve, HR NMIBC. ?? Learn how the treatment can potentially aid patients during the ongoing BCG shortage:

?? We spoke with Drs. Michael Whalen and Vincent Xu of The George Washington University Cancer Center on their recent analysis of neoadjuvant chemotherapy utilization for UTUC and the differences between radical nephroureterectomy and NAC as perioperative treatments. ?? Watch part one of this interview:

?? In our new roundtable discussion, Irbaz Riaz of Mayo Clinic and panelists Roopesh Kantala, MD, James Ewing, MD, and Chad Cherington, MD, of Ironwood Cancer and Research Centers delve into current approaches for managing metastatic #prostatecancer. ?? Learn about their insights into diagnosis, staging, and risk stratification:

?? There is a lack of data on the use of short-term ADT in with high-dose radiotherapy versus RT alone for patients with localized #prostatecancer. ?? Learn how the phase 3 GETUG 14 trial has analyzed ADT plus RT to gain more insight on these treatments:

?? Watch our new interview with Dr. Marc Greenstein of Advanced Urology on the findings from a recent real-world study demonstrating the OS benefit of #apalutamide compared to #enzalutamide in patients with metastatic castration-resistant #prostatecancer: